Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Death, Dying, and Disrespect: Failing to Honor Voices due to Systemic Barriers and Medicalization of End-of-Life Care We retrospectively analyzed patients with AML who sustained reduced left ...

Acute myeloid leukemia (AML) is the most common blood and bone marrow cancer in adults. Caused by an increase in immature cells that rapidly destroy and replace healthy blood cells (red and white ...

IDH1 mutations are seen in between 7% and 14% of AML patients – which is the most common form of leukaemia in adults with around 20,000 new cases in the US each year – and tend to be ...

Exposures to moderate-to-high doses of ionizing radiation have been associated with an increased risk of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic ...

(NASDAQ:GLYC) announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia ... in adults with newly diagnosed AML who are 60 ...

This emerging pattern further supports mipletamig's impact on treatment outcomes in frontline AML patients who are not fit for intensive chemotherapy and who would otherwise receive ven/aza as the ...